Literature DB >> 23424281

Impairment of TrkB-PSD-95 signaling in Angelman syndrome.

Cong Cao1, Mengia S Rioult-Pedotti, Paolo Migani, Crystal J Yu, Rakesh Tiwari, Keykavous Parang, Mark R Spaller, Dennis J Goebel, John Marshall.   

Abstract

Angelman syndrome (AS) is a neurodevelopment disorder characterized by severe cognitive impairment and a high rate of autism. AS is caused by disrupted neuronal expression of the maternally inherited Ube3A ubiquitin protein ligase, required for the proteasomal degradation of proteins implicated in synaptic plasticity, such as the activity-regulated cytoskeletal-associated protein (Arc/Arg3.1). Mice deficient in maternal Ube3A express elevated levels of Arc in response to synaptic activity, which coincides with severely impaired long-term potentiation (LTP) in the hippocampus and deficits in learning behaviors. In this study, we sought to test whether elevated levels of Arc interfere with brain-derived neurotrophic factor (BDNF) TrkB receptor signaling, which is known to be essential for both the induction and maintenance of LTP. We report that TrkB signaling in the AS mouse is defective, and show that reduction of Arc expression to control levels rescues the signaling deficits. Moreover, the association of the postsynaptic density protein PSD-95 with TrkB is critical for intact BDNF signaling, and elevated levels of Arc were found to impede PSD-95/TrkB association. In Ube3A deficient mice, the BDNF-induced recruitment of PSD-95, as well as PLCγ and Grb2-associated binder 1 (Gab1) with TrkB receptors was attenuated, resulting in reduced activation of PLCγ-α-calcium/calmodulin-dependent protein kinase II (CaMKII) and PI3K-Akt, but leaving the extracellular signal-regulated kinase (Erk) pathway intact. A bridged cyclic peptide (CN2097), shown by nuclear magnetic resonance (NMR) studies to uniquely bind the PDZ1 domain of PSD-95 with high affinity, decreased the interaction of Arc with PSD-95 to restore BDNF-induced TrkB/PSD-95 complex formation, signaling, and facilitate the induction of LTP in AS mice. We propose that the failure of TrkB receptor signaling at synapses in AS is directly linked to elevated levels of Arc associated with PSD-95 and PSD-95 PDZ-ligands may represent a promising approach to reverse cognitive dysfunction.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23424281      PMCID: PMC3570550          DOI: 10.1371/journal.pbio.1001478

Source DB:  PubMed          Journal:  PLoS Biol        ISSN: 1544-9173            Impact factor:   8.029


  92 in total

1.  Quaternary structure, protein dynamics, and synaptic function of SAP97 controlled by L27 domain interactions.

Authors:  Terunaga Nakagawa; Kensuke Futai; Hilal A Lashuel; Irene Lo; Kenichi Okamoto; Thomas Walz; Yasunori Hayashi; Morgan Sheng
Journal:  Neuron       Date:  2004-10-28       Impact factor: 17.173

2.  Molecular dissociation of the role of PSD-95 in regulating synaptic strength and LTD.

Authors:  Weifeng Xu; Oliver M Schlüter; Pascal Steiner; Brian L Czervionke; Bernardo Sabatini; Robert C Malenka
Journal:  Neuron       Date:  2008-01-24       Impact factor: 17.173

Review 3.  Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease.

Authors:  Akira Yoshii; Martha Constantine-Paton
Journal:  Dev Neurobiol       Date:  2010-04       Impact factor: 3.964

4.  Cyclic AMP controls BDNF-induced TrkB phosphorylation and dendritic spine formation in mature hippocampal neurons.

Authors:  Yuanyuan Ji; Petti T Pang; Linyin Feng; Bai Lu
Journal:  Nat Neurosci       Date:  2005-01-23       Impact factor: 24.884

5.  Increased expression of the immediate-early gene arc/arg3.1 reduces AMPA receptor-mediated synaptic transmission.

Authors:  Emiliano M Rial Verde; Jane Lee-Osbourne; Paul F Worley; Roberto Malinow; Hollis T Cline
Journal:  Neuron       Date:  2006-11-09       Impact factor: 17.173

6.  The involvement of brain-derived neurotrophic factor in hippocampal long-term potentiation revealed by gene targeting experiments.

Authors:  M Korte; V Staiger; O Griesbeck; H Thoenen; T Bonhoeffer
Journal:  J Physiol Paris       Date:  1996

7.  Endophilin B1 as a novel regulator of nerve growth factor/ TrkA trafficking and neurite outgrowth.

Authors:  Jun Wan; Anthony Y Cheung; Wing-Yu Fu; Chengbiao Wu; Mingjie Zhang; William C Mobley; Zelda H Cheung; Nancy Y Ip
Journal:  J Neurosci       Date:  2008-09-03       Impact factor: 6.167

8.  Long-lasting neurotrophin-induced enhancement of synaptic transmission in the adult hippocampus.

Authors:  H Kang; E M Schuman
Journal:  Science       Date:  1995-03-17       Impact factor: 47.728

9.  A cyclic peptide targeted against PSD-95 blocks central sensitization and attenuates thermal hyperalgesia.

Authors:  B W LeBlanc; M Iwata; A P Mallon; C N Rupasinghe; D J Goebel; J Marshall; M R Spaller; C Y Saab
Journal:  Neuroscience       Date:  2010-02-16       Impact factor: 3.590

10.  Arc/Arg3.1 is essential for the consolidation of synaptic plasticity and memories.

Authors:  Niels Plath; Ora Ohana; Björn Dammermann; Mick L Errington; Dietmar Schmitz; Christina Gross; Xiaosong Mao; Arne Engelsberg; Claudia Mahlke; Hans Welzl; Ursula Kobalz; Anastasia Stawrakakis; Esperanza Fernandez; Robert Waltereit; Anika Bick-Sander; Eric Therstappen; Sam F Cooke; Veronique Blanquet; Wolfgang Wurst; Benedikt Salmen; Michael R Bösl; Hans-Peter Lipp; Seth G N Grant; Tim V P Bliss; David P Wolfer; Dietmar Kuhl
Journal:  Neuron       Date:  2006-11-09       Impact factor: 17.173

View more
  75 in total

Review 1.  Excitatory/Inhibitory Balance and Circuit Homeostasis in Autism Spectrum Disorders.

Authors:  Sacha B Nelson; Vera Valakh
Journal:  Neuron       Date:  2015-08-19       Impact factor: 17.173

Review 2.  Pharmacological therapies for Angelman syndrome.

Authors:  Wen-Hann Tan; Lynne M Bird
Journal:  Wien Med Wochenschr       Date:  2016-01-12

Review 3.  Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches.

Authors:  Andrea de Bartolomeis; Gianmarco Latte; Carmine Tomasetti; Felice Iasevoli
Journal:  Mol Neurobiol       Date:  2013-09-03       Impact factor: 5.590

4.  Essential role of GluD1 in dendritic spine development and GluN2B to GluN2A NMDAR subunit switch in the cortex and hippocampus reveals ability of GluN2B inhibition in correcting hyperconnectivity.

Authors:  Subhash C Gupta; Roopali Yadav; Ratnamala Pavuluri; Barbara J Morley; Dustin J Stairs; Shashank M Dravid
Journal:  Neuropharmacology       Date:  2015-02-24       Impact factor: 5.250

Review 5.  Modulation of Synaptic Plasticity by Exercise Training as a Basis for Ischemic Stroke Rehabilitation.

Authors:  Jingjing Nie; Xiaosu Yang
Journal:  Cell Mol Neurobiol       Date:  2016-02-24       Impact factor: 5.046

6.  Seizure-like activity in a juvenile Angelman syndrome mouse model is attenuated by reducing Arc expression.

Authors:  Caleigh Mandel-Brehm; John Salogiannis; Sameer C Dhamne; Alexander Rotenberg; Michael E Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-06       Impact factor: 11.205

7.  Ferroportin deficiency impairs manganese metabolism in flatiron mice.

Authors:  Young Ah Seo; Marianne Wessling-Resnick
Journal:  FASEB J       Date:  2015-03-17       Impact factor: 5.191

8.  Cholinergic Grb2-Associated-Binding Protein 1 Regulates Cognitive Function.

Authors:  Nan-Nan Lu; Chao Tan; Ning-He Sun; Ling-Xiao Shao; Xiu-Xiu Liu; Yin-Ping Gao; Rong-Rong Tao; Quan Jiang; Cheng-Kun Wang; Ji-Yun Huang; Kui Zhao; Guang-Fa Wang; Zhi-Rong Liu; Kohji Fukunaga; Ying-Mei Lu; Feng Han
Journal:  Cereb Cortex       Date:  2018-07-01       Impact factor: 5.357

9.  Sodium-potassium ATPase emerges as a player in hippocampal phenotypes of Angelman syndrome mice.

Authors:  Jada J Hallengren; Ryan J Vaden
Journal:  J Neurophysiol       Date:  2014-02-05       Impact factor: 2.714

10.  E6AP in the brain: one protein, dual function, multiple diseases.

Authors:  Jimmy El Hokayem; Zafar Nawaz
Journal:  Mol Neurobiol       Date:  2013-10-05       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.